Michael Touchy, MD
Nephrology · New Orleans, LANPI 1346667532
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,769 of the $55,787 with a category attached, or 87.4%. Amgen accounts for 94.8% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $35,584, more than ten times the $673 reported in 2019. Among nephrology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 229 payments — averaging $243.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$53K
- Mallinckrodt Hospital Products Inc.$415
- AstraZeneca$365
- Aurinia Pharma U.S., Inc.$351
- Akebia Therapeutics Inc$256
- Vifor Pharma, Inc.$254
- plus $1K from 15 others
What the payments were for
- Speaking & faculty fees$48,76987%
- Travel & lodging$1,6283%
- Food & beverage$5,2529%
- Education$1380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 98 | $52,882 |
| Mallinckrodt Hospital Products Inc. | 12 | $415 |
| AstraZeneca(2 entities) | 19 | $365 |
| Aurinia Pharma U.S., Inc. | 9 | $351 |
| Akebia Therapeutics Inc | 14 | $256 |
| Vifor Pharma, Inc. | 15 | $254 |
| Bayer | 13 | $248 |
| Otsuka America Pharmaceutical, Inc. | 10 | $158 |
| Shire North American Group Inc | 2 | $132 |
| Mallinckrodt Enterprises LLC | 5 | $127 |
| Fresenius USA Marketing, Inc. | 7 | $125 |
| Radius Health, Inc. | 6 | $110 |
| Calliditas Therapeutics US Inc. | 4 | $86 |
| OPKO Pharmaceuticals, LLC | 5 | $68 |
| Travere Therapeutics, Inc. | 4 | $53 |
| Baxter Healthcare | 1 | $50 |
| Ardelyx, Inc. | 1 | $27 |
| Boehringer Ingelheim | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
| Cormedix Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$51,725
- TERLIVAZ$149
- LUPKYNIS$125
- NATPARA (PARATHYROID HORMONE)$121
How this compares
$55,787 in reported general payments places this provider in the 95th percentile of 206 nephrology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 12 | $1,076,726 |
| KerendiaFinerenone | 171 | $129,544 |
| VelphoroSucroferric Oxyhydroxide | 30 | $125,315 |
| FarxigaDapagliflozin Propanediol | 150 | $96,997 |
| VeltassaPatiromer Calcium Sorbitex | 45 | $72,203 |
| JardianceEmpagliflozin | 22 | $29,887 |
| Cinacalcet Hcl | 42 | $26,266 |
| Lanthanum Carbonate | 20 | $23,361 |
| LokelmaSodium Zirconium Cyclosilicate | 15 | $19,658 |
| Sevelamer Carbonate | 72 | $12,798 |
| Potassium Citrate ErPotassium Citrate | 156 | $12,162 |
| Bumetanide | 145 | $4,202 |
| Torsemide | 70 | $2,975 |
| Potassium Chloride | 58 | $2,583 |
| Mycophenolate Mofetil | 13 | $1,620 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $415 | $1,076,72612 claims |
| BayerKerendia | $248 | $129,544171 claims |
| Fresenius USA Marketing, Inc.Velphoro | $125 | $125,31530 claims |
| AstraZenecaFarxiga, Lokelma | $365 | $116,655165 claims |
| Boehringer IngelheimJardiance | $21 | $29,88722 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $19 | $95830 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 206 nephrology providers in Louisiana.
Other nephrology in New Orleans
- Juan Carlos VelezNew Orleans$282K
- Juan MedauraNew Orleans$14K
- Farshid YazdiNew Orleans$14K
- Mihran NaljayanNew Orleans$10K
- Rhea BhargavaNew Orleans$9K
- April FoxNew Orleans$8K
- Myra KleinpeterNew Orleans$7K
- Joshua LowentrittNew Orleans$7K
- Angela ReginelliNew Orleans$6K
- Francisco CruzNew Orleans$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.